查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1317945

黑色素瘤药物市场：依黑色素瘤类型、治疗方法- 2023-2030 年全球预测

Melanoma Drug Market by Type of Melanoma, Therapy - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2023 年，全球黑色素瘤治疗市场将达到 55.3606 亿美元，年复合成长率为 13.35%，预计到 2030 年将出现惊人增长，达到 133.2843 亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球黑色素瘤药物市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.黑色素瘤治疗药物的全球市场规模与预测为何？

2.在预测期内，COVID-19 对全球黑色素瘤治疗药物市场的阻碍因素与影响为何？

3. 在预测期内，全球黑色素瘤治疗药物市场需要投资哪些产品/细分市场/应用/领域？

4.全球黑色素瘤药物市场的竞争策略为何？

5. 全球黑色素瘤药物市场的技术趋势和法律规范是什么？

6.全球黑色素瘤治疗药物市场主要厂商的市占率为何？

7. 哪些型态和策略性措施被认为适合进入全球黑色素瘤药物市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 全球黑色素瘤和其他皮肤癌的盛行率上升
      • 专利到期延长导致生物相似药的使用
      • 发展中地区对具有成本效益的治疗方法的需求日益增长
    • 抑制因素
      • 缺乏创新和成功的治疗方法
    • 机会
      • 副作用的减少和效率的提高增加了对标靶治疗的需求
      • 继续进行研究和开发活动，推出有效的药物
    • 任务
      • 严格的法规政策和漫长的审批流程
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第6章以黑色素瘤类型分類的黑色素瘤治疗药物市场

  • 肢端雀斑样黑色素瘤
  • 雀斑样恶性黑色素瘤
  • 结节性黑色素瘤
  • 表浅黑色素瘤

第7章依疗法分類的黑色素瘤治疗药物市场

  • 化学处理
  • 免疫疗法
  • 标靶治疗

第8章美洲黑色素瘤药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第9章亚太黑色素瘤药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲黑色素瘤药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第11章竞争形势

  • FPNV定位矩阵
  • 市占率分析：主要企业
  • 竞争情境分析：主要企业

第12章上市公司名单

第13章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-0363DFE03683

The Global Melanoma Drug Market is forecasted to grow significantly, with a projected USD 5,536.06 million in 2023 at a CAGR of 13.35% and expected to reach a staggering USD 13,328.43 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Melanoma Drug Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Melanoma Drug Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type of Melanoma, market is studied across Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma, and Superficial Spreading Melanoma. The Nodular Melanoma is projected to witness significant market share during forecast period.

Based on Therapy, market is studied across Chemotherapy, Immunotherapy, and Targeted Therapy. The Chemotherapy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Melanoma Drug Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Melanoma Drug Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Melanoma Drug Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Melanoma Drug Market?

4. What is the competitive strategic window for opportunities in the Global Melanoma Drug Market?

5. What are the technology trends and regulatory frameworks in the Global Melanoma Drug Market?

6. What is the market share of the leading vendors in the Global Melanoma Drug Market?

7. What modes and strategic moves are considered suitable for entering the Global Melanoma Drug Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Melanoma Drug Market, by Type of Melanoma, 2022 vs 2030
  • 4.3. Melanoma Drug Market, by Therapy, 2022 vs 2030
  • 4.4. Melanoma Drug Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of melanoma and other skin cancers globally
      • 5.1.1.2. Increasing patent expiration leading to use of biosimilars
      • 5.1.1.3. Growing need for cost-effective therapeutics in developing regions
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of innovative and successful therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging demand for targeted therapy owing to reduced side effects and higher efficiency
      • 5.1.3.2. Ongoing research and development activities to introduce effective drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory policies and lengthy approval process
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Melanoma Drug Market, by Type of Melanoma

  • 6.1. Introduction
  • 6.2. Acral Lentiginous Melanoma
  • 6.3. Lentigo Maligna Melanoma
  • 6.4. Nodular Melanoma
  • 6.5. Superficial Spreading Melanoma

7. Melanoma Drug Market, by Therapy

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Immunotherapy
  • 7.4. Targeted Therapy

8. Americas Melanoma Drug Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Melanoma Drug Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Melanoma Drug Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. MELANOMA DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. MELANOMA DRUG MARKET SIZE, 2022 VS 2030
  • FIGURE 3. MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2022 VS 2030 (%)
  • FIGURE 5. MELANOMA DRUG MARKET SIZE, BY THERAPY, 2022 VS 2030 (%)
  • FIGURE 6. MELANOMA DRUG MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. MELANOMA DRUG MARKET DYNAMICS
  • FIGURE 8. MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. MELANOMA DRUG MARKET SIZE, BY THERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. MELANOMA DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 5. MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 10. MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY TYPE OF MELANOMA, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 100. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 101. MELANOMA DRUG MARKET LICENSE & PRICING